NetworkNewsBreaks

TuesdaySep 07, 2021 10:30 am

NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Results of Human Clinical Study Showing Effective, Safe BP Reduction

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has announced that its human clinical study HYPER-H21-2, which features LEXX’s patented DehydraTECH(TM)-processed cannabidiol (“CBD”), demonstrates up to a 23% decrease in blood pressure when compared to placebo. According to the announcement, partial results are being released today with additional blood pressure subset analyses, sleep quality and all other data analyses will be reported when complete. Partial results indicate that at selected times during the 24-hour study, volunteers with mild to moderate hypertension averaged as much as a 20 mmHg (i.e., 23%) decrease in BP relative to placebo, with volunteers…

Continue Reading

TuesdaySep 07, 2021 9:59 am

NetworkNewsBreaks – Grapefruit USA Inc. (GPFT) Issues Update Concerning Formation of Joint Venture, Potential Acquisition

Grapefruit USA (OTCQB: GPFT), a premiere, fully licensed California-based cannabis company, today provided further updates to its March and May 2021 announcements regarding discussions with a Canadian cannabis company surrounding development of a memorandum of understanding (“MOU”). The MOU sets forth terms under which the parties could enter into a joint venture to jointly manufacture, distribute and market Grapefruit’s products, including, but not limited to, Grapefruit’s patented disruptive Hourglass(TM) THC/cannabinoid time-release delivery cream throughout Canada. “Execution of the MOU moved the entire process forward, as we now more clearly understand each other’s overall goals and priorities as well as the…

Continue Reading

TuesdaySep 07, 2021 9:51 am

NetworkNewsBreaks – reAlpha Enters New Partnership with Carthagos, Creating End-to-End Product Studio

reAlpha, a cutting-edge technology company launching an innovative platform empowering everyone to invest in the $1.2 trillion short-term rental market, has announced its new partnership with Carthagos, a global design and product studio specializing in the strategic development of brands and digital products. According to the update, reAlpha has taken 25% equity in Carthagos, and reAlpha’s Chief Marketing Officer, Christie Currie, will join Carthagos’ board of directors. This partnership is in addition to the investment in Naamche that reAlpha announced recently. “From the start of reAlpha, we have always asked ‘who’ before ‘how.’ In a short period of time, we…

Continue Reading

TuesdaySep 07, 2021 9:33 am

NetworkNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Announces Ownership Increase in Subsidiary Holding

AnPac Bio-Medical Science (NASDAQ: ANPC) subsidiary AnPac Bio-Medical Science (Lishui) Co. Ltd. has increased its holding in AnPai (Shanghai) Healthcare Management Consultant Co. Ltd., one of its subsidiaries; the increase came after approval was granted by the company audit committee and board of directors. The company announced that in late August 2021 it finalized the share structure registration amendment with the local Administration Management Bureau. Before making the decision, company officials conducted rigorous due diligence that included obtaining financial and legal audits and appraisals by a qualified appraiser. AnPac Bio-Medical Science is a biotechnology company with operations in China and…

Continue Reading

FridaySep 03, 2021 2:50 pm

NetworkNewsBreaks – InnerScope Hearing Technologies Inc. (INND) to Be Featured in ‘New to the Street’ Broadcast

InnerScope Hearing Technologies (OTC: INND) will be featured in an upcoming segment of FMW Media’s “New to the Street” nationally syndicated show. The company will be one of eight featured on Sunday, Sept. 5, 2021, with the broadcast airing at 10 to 11 a.m. ET. The segment will include an interview with INND CEO Matthew Moore, who will inform viewers about the company’s emerging and disruptive leadership in the direct-to-consumer (“DTC”) hearing technology space. Moore will discuss INND’s successful direct-marketing strategy, helping to get the company’s hearing aids, selling at a fraction of the cost of products offered by major…

Continue Reading

FridaySep 03, 2021 1:54 pm

NetworkNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Proprietary Technology Elevating Quantity of Drugs Delivered Across Blood-Brain Barrier by 1,900%

Lexaria Bioscience Corp. (NASDAQ: LEXX) recently announced that a tolerability and pharmacokinetic study, performed by an independent, premier animal testing laboratory in the U.S., had demonstrated that administration of colchicine using its proprietary DehydraTECH(TM) resulted in increased delivery. “Colchicine is an approved therapeutic with anti-inflammatory effects primarily used to treat gout and cardiac conditions such as pericarditis. It was the latest of several drugs Lexaria tested with known SARS-CoV-2/COVID-19 antiviral properties after it showed potent effects in mitigating the cytokine storm associated with the virus. Additionally, colchicine is occasionally used to treat emergent pericarditis in children, which would make the…

Continue Reading

FridaySep 03, 2021 1:39 pm

NetworkNewsBreaks – BevCanna Enterprises Inc.’s (CSE: BEV) (OTCQB: BVNNF) (FSE:7BC) Subsidiary Supplying Bottled Water to BC Firefighters Sourced from the Very Land They Protect

BevCanna Enterprises (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC), a diversified health and wellness beverage and natural products company, recently announced that its wholly owned subsidiary Naturo Group had been selected to manufacture and supply a special, limited-edition run of its TRACE-branded, alkaline spring water to the BC Wildfire Services, which employs 1,100 Type 1 firefighters. BevCanna president Melise Panetta is quoted in a recent article as saying, “We are proud to be providing the firefighters with a special edition of our TRACE-branded natural 7.7pH alkaline spring water, sourced directly from our proprietary BC interior aquifer – the very land and…

Continue Reading

FridaySep 03, 2021 1:27 pm

NetworkNewsBreaks – FingerMotion Inc. (FNGR) on Path to Complete Insurtech Model by YE 2021

FingerMotion (OTCQX: FNGR) is an evolving technology company with three operational and revenue-generating business units – TPS, SMS & MMS, and Big Data – with plans to make a fourth division, the rich communication services (“RCS”), operational in due course. “Earlier this year, buoyed by its big data product dubbed Sapientus, the company forayed into insurtech through its partnership with Pacific Life Re-insurance, which appears to have set the foundation for similar alliances in the sector,” reads a recent article. “Since then, FNGR has entered into an agreement with Happy Life Insurance to create an innovative, data-driven insurance business model…

Continue Reading

FridaySep 03, 2021 12:12 pm

NetworkNewsBreaks – Infobird Software Co. Ltd. (NASDAQ: IFBD) Helping Companies Build Long-Term Customer Relationships

Infobird (NASDAQ: IFBD), a business-to-business (“B2B”) artificial intelligence (“AI”) solutions company, recently announced the launch of its call center. “The WeChat call center is designed to help businesses build an automated and personalized private domain traffic operation platform that will help the B2C clients achieve major upgrades while drawing on the advantages of the powerful WeChat ecosystem for interacting with customers,” reads a recent article. Companies seeking to use their resources in the most effective manner possible to acquire and retain consumers have turned to Infobird, which, through the WeChat call center and other technologies, is facilitating just that. “Using…

Continue Reading

FridaySep 03, 2021 12:00 pm

NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Featured in Article as Stock That Is ‘Shaping up to Be a Brilliant Investment’

Cybin (NEO: CYBN) (NYSE American: CYBN), a life sciences company focused on advancing psychedelic pharmaceutical therapeutics for various psychiatric and neurological conditions, was highlighted in a Motley Fool article titled, “Buying Cybin Stock Right Now Could Be a Brilliant Move.” The piece, written by Alex Carchidi, delves into CYBN as one of those investment opportunities in places outside the mainstream. “Cybin (NYSE: CYBN) is a biotech that's developing mental illness treatments derived from widely illegal psychedelic chemicals like psilocybin (best known as the active compound in ‘magic mushrooms’). Based on a swath of extremely positive coverage in the scientific literature,…

Continue Reading